heard you are adding reps for new GI indication. Anyone know if it’s just a few, or flooding the offices obnoxiously??
The reps were added on January 1. ~90+ reps in total were added from another division. We are flooding the offices obnoxiously as usual. It's the strategy from the 1990's. More reps must equal more sales...
This was just a shift of headcount from rheumatology to GI. Stelara was a bust in rheumatology, and has an insane price tag in GI because of dosing...
In the next year there are 4 block buster drugs that will not only compete but actually destroy Janssen GI business. Doubling the sales force now is moronic. Plus everyone knows that Janssen drugs are the most expensive. And Docs hate that! I’m glad I’m not in that sales force. I can’t see them having a job much longer. The job cuts coming in late 2019 are going to be heavy and deep.
I talked to a former rep today who got recruited to sell a biologic competitor. He accepted a 160k base salary, 20k sign on bonus. He’s going to destroy his JBI region with his product. Reps there are scared to death of him selling against them.
We will never cut our valued sales force. It it cheaper to make your life miserable and have you quit. Marty
The shift of head count to expand GI makes no sense. There are not that many patients, and as we keep increasing headcount you just restrict access. Lots of joint calls are being made, and this proves there is a marginal benefit to increased headcount.
The shift of headcount from rheumatology to GI makes sense given the insane price tag for Stelara. A Stelara GI patient is worth 2x compared to PSA.
Of course they are more expensive. How else are we going to pay for all of our lawsuits and f**k ups?
Stelara is a shadow of a drug compared to Remicade. We are selling bad medicine and I am sick of being told to misrepresent the truth to fill the pockets of JnJ with higher margin products. Bad medicine is bad for everyone.
